Drug Trial Radar · NCT05551104
Safest Choice of Antihypertensive Regimen for Postpartum Hypertension
Last checked: Nov 19, 2026Latest source record: Feb 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
500
Planned (sponsor's estimate)
Start
May 8, 2023
Primary completion
Dec 2027
Study completion Dec 2027
Sponsor
- Lead sponsor
- Loma Linda UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Sep 22, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this investigator-initiated randomized control trial is to determine whether oral Nifedipine versus oral Labetalol is superior in controlling high blood pressures in the postpartum period.
Conditions
- Postpartum Complication
- Maternal Hypertension
- High Blood Pressure
Interventions
Oral NifedipineDrug
Administration of oral nifedipine to control postpartum hypertension.
Oral LabetalolDrug
Administration of oral labetalol to control postpartum hypertension.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Composite maternal morbidityTime frame: 0-6 weeks following delivery
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Loma Linda University Health
Loma Linda, California · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.